Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Post by Art365on Apr 05, 2011 11:12am
184 Views
Post# 18386920

Dilution

DilutionSomebody wrote on this board about an eventual devastating dilution resulting from the conversion of convertible notes, etc. The figure mentioned was 700 million shares, taken from the Q3 report. But this was an hypothetic scenario, based on a conversion price of 0,09$ per share. Let's look at the facts:

The 6 million$ convertible notes of the landlord were converted at 0,29$ per share, so 20,6 million shares were issued, rather than 67 million which would have been issued at 0,09. There were also 83 million preferred shares outstanding at the end of Q3 2010. But 14,8 million preferred shares have been converted to 16 million common shares during the previous 12 months, at an effective conversion rate of 0,93$ per share. Finally, at the end of Q3 2010, there were 21 million$ of convertible notes expiring in 2014, 13 million$ expiring in 2026 and 0,5 million$ expiring in 2027.

So the real situation could be much different from this apocalyptic scenario. In fact, the more the shares rise, the more their real value increases.

Bullboard Posts